Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI model aims to predict Post-Surgery bleeding in stomach cancer patients

NCT ID NCT07525765

Knowledge-focused Sponsor: First Affiliated Hospital of Zhejiang University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is developing an AI tool to predict the risk of serious bleeding after stomach cancer surgery. Researchers will collect data from 7,000 adult patients who had their stomach removed due to cancer. The goal is to help doctors decide earlier if a second surgery is needed, potentially saving lives. No new treatments are being tested; this is purely an observational study to improve decision-making.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 7,000 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study includes adults (≥18y) with confirmed primary gastric cancer undergoing elective radical gastrectomy (proximal/distal/total) with D1+/D2 lymphadenectomy at \[Center\]. The cohort comprises retrospective (\[2015.6\]-\[2026.2\]) and prospective (\[2026.3\]-present) arms. Emergency, palliative, or multi-organ resections are excluded to ensure homogeneity. The investigators anticipate enrolling 7000 patients. The primary outcome is postoperative hemorrhage requiring surgical re-intervention within 30 days. Estimated incidence is 0.5%-2.0%. To address this class imbalance, the AI model will employ stratified sampling and cost-sensitive learning.This population represents standard candidates for curative surgery in tertiary centers. By excluding extreme cases, the model is optimized for risk stratification in routine elective settings, where early warnings prevent catastrophic outcomes. Prospective data will validate real-time generalizability.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age: Patients aged ≥ 18 years. 2. Diagnosis: Histologically confirmed primary gastric cancer. 3. Surgical Procedure: Underwent radical gastrectomy (including proximal, distal, or total gastrectomy). 4. Consent: Provision of written informed consent (required specifically for the prospective phase). 5. Data Completeness: Availability of complete preoperative clinical data and postoperative follow-up records covering at least the first 15 days post-surgery. 6. Oncological History: No history of other primary malignant tumors. Exclusion Criteria: 1. Surgical Type: Patients who underwent non-radical resection or emergency surgery. 2. Data Quality: Missing rate of key data fields exceeds 20%. 3. Preoperative Condition: Presence of severe preoperative infection or organ failure. 4. Follow-up Compliance: Unwillingness to participate in prospective follow-up or inability to complete the follow-up schedule (applicable only to the prospective phase).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastrectomy for gastric cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

gastric cancer gastric neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastrectomy for gastric cancer Gastric cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The First Affiliated Hospital, Zhejiang University School of Medicine Yuhang Campus

    RECRUITING

    Hangzhou, Zhejiang, 330100, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.